MedTrace Logo

Multicenter Investigation of Limitation of Infarct Size (MILIS)

NCT00000493 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-07-12

No results posted yet for this study

Summary

To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.

Conditions

Interventions

DRUG

propranolol

DRUG

hyaluronidase

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Eugene Braunwald · Harvard Medical School, Peter Bent Brigham Hospital

  • Allan Jaffee · Washington University School of Medicine

  • James Willerson · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1977-09-30
Completion
1985-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000493 on ClinicalTrials.gov